Posted by Michael Wonder on 04 Aug 2018
EMA grants PRIME status for Roche Huntington's drug
3 August 2018 - The EMA has granted PRIME designation to Roche's RG6042 for treatment of Huntington’s disease.
PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options, providing a pathway for accelerated evaluation by the agency, and thus potentially enabling them to reach patients earlier.
RG6042 has the potential to be the first therapy targeting the underlying cause of Huntington’s disease, a fatal neurodegenerative rare disease.
